AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7280386 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive (R) loads at near threshold
Number of subjects: 6
Study 7280386 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive (R) loads at 4-5 times threshold
Number of subjects: 6
Study 7280386 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip responses during R loaded breaths
Number of subjects: 6
Study 7280386 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip responses during E loaded breaths
Number of subjects: 6
Study 6199481 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) IV daily for 10 days
Number of subjects: 57
Study 6199481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine, bleomycin, and cisplatin (VBD)
Number of subjects: 57
Study 31597207 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cigarette (EC) starter kit
Number of subjects: 886
Study 31597207 — intervention group
Group type: COMPARATOR
Intervention: nicotine replacement therapy (NRT)
Number of subjects: 886
Study 31597207 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cigarettes (EC)
Number of subjects: 886
Study 29339032 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 35
Study 27266867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fufangdanshen (FFDS) tablets, 3 tablets three times per day for 24 weeks
Number of subjects: 240
Study 27266867 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 tablets three times per day for 24 weeks
Number of subjects: 240
Study 24473459 — intervention group
Group type: EXPERIMENTAL
Intervention: Palaeolithic-type diet (PD)
Number of subjects: 70
Study 24473459 — intervention group
Group type: COMPARATOR
Intervention: Nordic Nutrition Recommendations (NNR) diet
Number of subjects: 70
Study 22748456 — intervention group
Group type: EXPERIMENTAL
Intervention: Contusion group (ARDS induced by lung contusion)
Number of subjects: 40
Study 22748456 — intervention group
Group type: COMPARATOR
Intervention: Control group (without lung contusion and ARDS)
Number of subjects: 40
Study 20363879 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (7-36)-amide
Number of subjects: 0
Study 20363879 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-4 (Ex-4)
Number of subjects: 0
Study 20363879 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin (Ex)-3
Number of subjects: 0
Study 20363879 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-4(3-39)
Number of subjects: 0
Study 18684178 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) guidance
Number of subjects: 10
Study 18684178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EUS guidance)
Number of subjects: 10
Study 26462765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucinex 1200 mg (2 x 600 mg extended release tablets)
Number of subjects: 38
Study 11518588 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic analysis of voice parameters (jitter, shimmer, Fo tremor, HNR) during treatment
Number of subjects: 46
Study 11518588 — intervention group
Group type: COMPARATOR
Intervention: Control group of children without voice pathology
Number of subjects: 46
Study 9623511 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide treatment for 1 or 2 months
Number of subjects: 9
Study 9623511 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide treatment for 1 month
Number of subjects: 9
Study 9623511 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide treatment for 2 months
Number of subjects: 9
Study 7512285 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term tube thoracostomy drainage (group 2)
Number of subjects: 25
Study 7512285 — intervention group
Group type: COMPARATOR
Intervention: Standard tube thoracostomy drainage (group 1)
Number of subjects: 25
Study 3335825 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinyl estradiol
Number of subjects: 0
Study 3335825 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms ethinyl estradiol
Number of subjects: 0
Study 3335825 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms ethinyl estradiol
Number of subjects: 0
Study 3335825 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of estrogen-progestin preparation
Number of subjects: 0
Study 3335825 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3335825 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study 29757661 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine sodium administered daily either as the whole dose q 24 hr or as half the dose q 12 hr, starting at 0.1 mg/10 lb (0.022 mg/kg) for approximately 6 months
Number of subjects: 92
Study 26419527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA) treatment
Number of subjects: 557
Study 26419527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment protocol deviations
Number of subjects: 557
Study 26419527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment deviations
Number of subjects: 557
Study 25214775 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Number of subjects: 205
Study 25214775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 22760010 — intervention group
Group type: COMPARATOR
Intervention: On-demand nutritional support (n=26: nutritional intervention if weight loss >5%)
Number of subjects: 53
Study 22760010 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive nutritional support (n=27: regular dietary advice plus energy‐ and protein‐rich evening snack)
Number of subjects: 53
Study 21428195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hindmilk
Number of subjects: 0
Study 21428195 — intervention group
Group type: COMPARATOR
Intervention: 12.5% Sucrose
Number of subjects: 0
Study 21428195 — intervention group
Group type: COMPARATOR
Intervention: Distilled Water
Number of subjects: 0
Study 17913605 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and pethidine (Group M: n=27)
Number of subjects: 54
Study 17913605 — intervention group
Group type: COMPARATOR
Intervention: Propofol and fentanyl (Group P: n=27)
Number of subjects: 54
Study 17319111 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine, Clonidine, L-NMMA (nonselective alpha-adrenoceptor agonists)
Number of subjects: 0
Study 17319111 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine (selective alpha1-adrenoceptor agonist)
Number of subjects: 0
Study 17319111 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 17319111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 0
Study 12095191 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery condition
Number of subjects: 68
Study 12095191 — intervention group
Group type: COMPARATOR
Intervention: No-imagery control condition
Number of subjects: 68
Study 9796229 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ratings with an immediate test
Number of subjects: 0
Study 9796229 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ratings with a delayed test
Number of subjects: 0
Study 9796229 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed ratings with a delayed test
Number of subjects: 0
Study 7707598 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based prevention program with annual provider training workshops and ongoing consultation
Number of subjects: 3597
Study 7707598 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based prevention program with videotaped training and no consultation
Number of subjects: 3597
Study 7707598 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (controls)
Number of subjects: 3597
Study 2710801 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion consumption (70 g raw onion daily for 7 days)
Number of subjects: 12
Study 2710801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger consumption (5 g raw ginger daily for 7 days)
Number of subjects: 12
Study 1016964 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 30
Study 1016964 — intervention group
Group type: COMPARATOR
Intervention: Serial echocardiography
Number of subjects: 30
Study 31600109 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous PRP gel
Number of subjects: 69
Study 31600109 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 69
Study 31600109 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 69
Study 30083752 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record‐embedded mailed fecal immunochemical test (FIT) outreach program
Number of subjects: 41193
Study 30083752 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41193
Study 27617680 — intervention group
Group type: EXPERIMENTAL
Intervention: Webcam Lidcombe Program treatment
Number of subjects: 49
Study 27617680 — intervention group
Group type: COMPARATOR
Intervention: Standard Lidcombe Program treatment
Number of subjects: 49
Study 24443982 — intervention group
Group type: EXPERIMENTAL
Intervention: Three weeks of plaster cast immobilization
Number of subjects: 0
Study 24443982 — intervention group
Group type: COMPARATOR
Intervention: Five weeks of plaster cast immobilization
Number of subjects: 0
Study 22405570 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly gemcitabine followed by erlotinib at disease progression (arm A)
Number of subjects: 100
Study 22405570 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib followed by gemcitabine at progression (arm B)
Number of subjects: 100
Study 19885979 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection according to baseline characteristics
Number of subjects: 8033
Study 19885979 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic targeting
Number of subjects: 8033
Study 19885979 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate adjustment
Number of subjects: 8033
Study 19885979 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection for targeted treatment effect
Number of subjects: 8033
Study 19885979 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic targeting for targeted treatment effect
Number of subjects: 8033
Study 17189085 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula containing 2 x 10(7) colony-forming units of Bifidobacterium longum BL999 and 4 g/L of prebiotic mixture (90% galacto-oligosaccharides and 10% fructo-oligosaccharides)
Number of subjects: 138
Study 17189085 — intervention group
Group type: COMPARATOR
Intervention: Control formula (not specified)
Number of subjects: 138
Study 15726029 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 69
Study 15726029 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 69
Study 15726029 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 69
Study 12498548 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐compartment conductive plastic tubing liquid cooling/warming garment (LCWG) with inlet water temperatures of 8‐45 degrees C
Number of subjects: 0
Study 12498548 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlet water temperature of 8 degrees C
Number of subjects: 0
Study 12498548 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlet water temperature of 45 degrees C
Number of subjects: 0
Study 12498548 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat transfer calculation standardized per unit tube length and flow rate
Number of subjects: 0
Study 12498548 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual thermal profiles design
Number of subjects: 0
Study 9892571 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg intramuscular piroxicam
Number of subjects: 64
Study 9892571 — intervention group
Group type: COMPARATOR
Intervention: 75 mg intramuscular diclofenac sodium
Number of subjects: 64
Study 7539625 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOP-B
Number of subjects: 18
Study 7539625 — intervention group
Group type: EXPERIMENTAL
Intervention: F-MACHOP
Number of subjects: 18
Study 2126198 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined oestrogen/progestogen therapy (2 mg of 17 beta‐oestradiol combined with 1 mg of norethisterone acetate orally each day continuously for 5 years)
Number of subjects: 37
Study 2126198 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined oestrogen/progestogen therapy
Number of subjects: 37
Study 2126198 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched untreated women)
Number of subjects: 37
Study 389150 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidine hydrochloride (20 to 35 mg/kg per day perorally)
Number of subjects: 14
Study 389150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30412909 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenous Counselling And Nicotine (ICAN) QUIT in Pregnancy intervention including educational resource packages, live interactive webinars, treatment manuals, patient resources, carbon monoxide (CO) meters, and oral Nicotine Replacement Therapy (NRT).
Number of subjects: 22
Study 30412909 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenous Counselling And Nicotine (ICAN) QUIT in Pregnancy intervention.
Number of subjects: 22
Study 28263812 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 1060
Study 28263812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1060
Study 24994768 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (PRE) program, 12 weeks, twice a week, using machines with free weights at 50% and 70% of one-repetition maximum (1RM).
Number of subjects: 60
Study 24994768 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) remained on a waiting list for physical therapy.
Number of subjects: 60
Study 21584847 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels measured by VIDAS D-dimer Exclusion (bioMerieux)
Number of subjects: 390
Study 21584847 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels measured by STA Liatest D-dimer (DiagnosticaStago)
Number of subjects: 390
Study 21584847 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels measured by HemosIL D-dimer and HemosIL D-dimer HS (Instrumentation Laboratory)
Number of subjects: 390
Study 21584847 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels measured by Innovance D-dimer (Siemens)
Number of subjects: 390
Study 21584847 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels measured by AutoDimer (Trinity Biotech)
Number of subjects: 390
Study 20876669 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Number of subjects: 62
Study 20876669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric gluconate
Number of subjects: 62
Study 20876669 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline levels)
Number of subjects: 62
Study 19118954 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg oxycodone (OXY)/487 mg acetaminophen (ACET)
Number of subjects: 20
Study 19118954 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg oxycodone (OXY)/975 mg acetaminophen (ACET)
Number of subjects: 20
Study 19118954 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg hydrocodone (HYD)/487 mg acetaminophen (ACET)
Number of subjects: 20
Study 19118954 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg hydrocodone (HYD)/975 mg acetaminophen (ACET)
Number of subjects: 20
Study 19118954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19118954 — intervention group
Group type: COMPARATOR
Intervention: 975 mg acetaminophen (ACET)
Number of subjects: 20
Study 17971620 — intervention group
Group type: EXPERIMENTAL
Intervention: Community rehabilitation program participants
Number of subjects: 83
Study 17971620 — intervention group
Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 83
Study 15626251 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty
Number of subjects: 30
Study 15626251 — intervention group
Group type: COMPARATOR
Intervention: Preoperative measurements
Number of subjects: 30
Study 15626251 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative measurements (4 and 9 months)
Number of subjects: 30
Study 15626251 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual case
Number of subjects: 30
Study 11374113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage monophasic oral contraceptives (OC) - days 5-8
Number of subjects: 9
Study 11374113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage monophasic oral contraceptives (OC) - days 19-21
Number of subjects: 9
Study 11374113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage monophasic oral contraceptives (OC) - run 5 days 5-8
Number of subjects: 9
Study 11374113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage monophasic oral contraceptives (OC) - run 5 days 19-21
Number of subjects: 9
Study 9589244 — intervention group
Group type: EXPERIMENTAL
Intervention: high‐mixture 75/25 insulin lispro/NPL insulin
Number of subjects: 30
Study 9589244 — intervention group
Group type: EXPERIMENTAL
Intervention: mid‐mixture 50/50 insulin lispro/NPL insulin
Number of subjects: 30
Study 9589244 — intervention group
Group type: EXPERIMENTAL
Intervention: low‐mixture 25/75 insulin lispro/NPL insulin
Number of subjects: 30
Study 9589244 — intervention group
Group type: EXPERIMENTAL
Intervention: insulin lispro
Number of subjects: 30
Study 9589244 — intervention group
Group type: EXPERIMENTAL
Intervention: NPL insulin
Number of subjects: 30
Study 15278585 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropinized group (0.015 mg.kg(‐1) i.m.)
Number of subjects: 43
Study 15278585 — intervention group
Group type: COMPARATOR
Intervention: Non‐atropinized group (A(‐))
Number of subjects: 43
Study 3924984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium (CS) 20 mg inhaled four times daily
Number of subjects: 13
Study 3924984 — intervention group
Group type: COMPARATOR
Intervention: Long-acting Theophylline (LAT) administered twice daily to achieve mean blood levels of 14.0 +/- 1.6 SEM micrograms per milliliters
Number of subjects: 13
Study 3924984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium (CS)
Number of subjects: 13
Study 3924984 — intervention group
Group type: COMPARATOR
Intervention: Long-acting Theophylline (LAT)
Number of subjects: 13
Study 30272170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (Trulicity®) 1.5 mg
Number of subjects: 20
Study 30272170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 20
Study 29160002 — intervention group
Group type: EXPERIMENTAL
Intervention: J‐Tip with 1% lidocaine
Number of subjects: 58
Study 29160002 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthetic (TA) cream
Number of subjects: 58
Study 26775671 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT), 4 sessions at 2‐week intervals
Number of subjects: 40
Study 26775671 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate (0.05%), daily for 8 weeks
Number of subjects: 40
Study 26775671 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT)
Number of subjects: 40
Study 26775671 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate (0.05%)
Number of subjects: 40
Study 25252230 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 212
Study 25252230 — intervention group
Group type: EXPERIMENTAL
Intervention: MD
Number of subjects: 212
Study 25252230 — intervention group
Group type: EXPERIMENTAL
Intervention: AD
Number of subjects: 212
Study 23248832 — intervention group
Group type: COMPARATOR
Intervention: CD-ROM
Number of subjects: 29
Study 23248832 — intervention group
Group type: COMPARATOR
Intervention: Simulation
Number of subjects: 29
Study 23248832 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination
Number of subjects: 29
Study 19763992 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 21
Study 19763992 — intervention group
Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 21
Study 17894707 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS)
Number of subjects: 0
Study 17894707 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision (SE)
Number of subjects: 0
Study 17894707 — intervention group
Group type: COMPARATOR
Intervention: Primary BCC
Number of subjects: 0
Study 17894707 — intervention group
Group type: COMPARATOR
Intervention: Recurrent BCC
Number of subjects: 0
Study 15048062 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue therapy combining amsacrine 120 mg/m(2)/day (days 1-3), cytarabine 1 g/m(2)/12 h (days 1-5), and etoposide 100 mg/m(2)/day (days 1-5)
Number of subjects: 40
Study 15048062 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue therapy combining amsacrine, cytarabine, and etoposide
Number of subjects: 40
Study 12516985 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian statistical methods for design and analysis of cost-effectiveness trials
Number of subjects: 0
Study 9421649 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 pitch helical CT
Number of subjects: 30
Study 9421649 — intervention group
Group type: COMPARATOR
Intervention: 1.0 pitch helical CT
Number of subjects: 30
Study 9421649 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT
Number of subjects: 30
Study 8556567 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) containing BKC
Number of subjects: 22
Study 8556567 — intervention group
Group type: EXPERIMENTAL
Intervention: BKC plus placebo
Number of subjects: 22
Study 8556567 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 22
Study 2169077 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (subcutaneous injection once daily)
Number of subjects: 40
Study 2169077 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous injection once daily)
Number of subjects: 40
Study 2169077 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 40
Study 40584 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cimetidine (1 g daily for 1 week)
Number of subjects: 10